PharmTech Drug Digest 11.20
News|Articles|May 5, 2016

CPhI China Returns to the Shanghai New International Exhibition Center

CPhI China is expected to bring together approximately 35,000 attendees from more than 120 countries worldwide.

CPhI China will return to the Shanghai New International Exhibition Center China, from June 21­–23, 2016. The event will be held in conjunction with Pharmaceutical Machinery and Equipment Convention China (P-Mec China) and will co-locate with ICSE, BioPh, Innopack, LABWorld, NEX China, P-Logi, Clean Room & EP, and Hi China, co-located with Fi Asia-China.

CPhI and P-MEC China 2016 will accommodate more than 2800 exhibitors‑including more than 1130 pharmaceutical ingredients exhibitors; 400 biopharmaceutical and natural extracts specialists; 500 pharmaceutical machinery professionals; and 150 pharmaceutical packaging, materials and drug delivery experts. CPhI China’s four-day program will include more than 182 speakers, presenting 50 seminars, 24 high level forums, and two C-level networking events across three days.

Some new features at CPhI China will include:

  • The Supplier Finder System, an interactive floor plan that allows visitors to locate suppliers, based on the search by a company name, product name, or booth number

  • The matchmaking program, which allows attendees to pre-arrange meetings with exhibitors

  • CPhI TV will conduct live interviews with companies on the show floor

  • Natural Extract Discover tours will introduce visitors to key players in the natural extract sector

  • Innovation Tours will present attendees with functional and insulin packaging solutions in the Chinese market.

CPhI China is expected to bring together approximately 35,000 attendees from more than 120 countries worldwide. Companies will be represented in 12 dedicated product zones, several of which include APIs, outsourcing, CRO/CMO, packaging, biopharmaceuticals, natural extracts, and machinery.

CPhI has worked with Pharmaceutical Technology to develop a program for the show. Pharmaceutical Technology and CPhI China are UBM plc brands.

Source: CPhI 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.